With an oversubscribed $30 million series B in hand, Carlsmed Inc. is in a good posture to take the next steps in its plan to make its personalized spinal implants central to ending frequent revisions in spine surgery. The company’s Aprevo devices, which are 3D printed for each patient, received FDA breakthrough device designation and 510(k) clearance in late 2020.
LONDON – Quell Therapeutics Ltd. has raised $156 million in an oversubscribed series B, enabling it to start a phase I/II trial of its engineered T regulatory (Treg) cell therapy for promoting long-term immune tolerance in liver transplant patients, averting the need for chronic immunosuppression.
Shouti Inc. raised $100 million in a series B round led by BVF Partners LP to advance its discovery platform for designing oral medicines and to speed up the development of its candidates. The Shanghai and California-based company has secured a total of $158 million in funding so far.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
Osso VR has raised $27 million in a series B financing led by GSR Ventures. The funds will be used to accelerate expansion of its library and virtual reality (VR)-powered surgical training and assessment platform.
HONG KONG – Splisense Ltd. has closed a $28.5 million series B financing that it said will support pipeline development including its lead antisense oligonucleotide candidate, SPL84-23, for the potential treatment of cystic fibrosis. The Jerusalem-based company, which develops mRNA-altering therapies for CF and other genetic pulmonary diseases, attracted support for the round from Orbimed, Israel Biotech Fund, Biotel Ltd. and the Cystic Fibrosis Foundation.
HONG KONG – Pharmcadd Co. Ltd., a developer of an artificial intelligence (AI) and physics-based drug discovery platform, bagged ₩17.3 billion (US$15.5 million) in its series B funding. This brings the total funds raised since its establishment to $22 million.
HONG KONG – Beijing Stonewise Technology Co. Ltd., a med-tech firm that uses artificial intelligence (AI) to aid in the discovery of small molecule drugs, closed series B and B+ financing rounds that added $100 million to its pocket. The company intends to use the proceeds to upgrade its AI-enabled drug discovery platform.
Chinese eye disease specialist Arctic Vision Biotechnology Co. Ltd. raised more than $100 million in a series B financing round. The clinical-stage company will use the funds to initiate a phase III trial for its core asset, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for uveitic macular edema in China this year.
